Perimeter Medical Imaging AI (TSX-V:PINK, OTC:PYNKF) announced the publication of a new white paper featuring three case studies involving the commercial use of its Perimeter S-Series Optical Coherence Tomography (OCT) technology.
The Perimeter S-Series OCT is an ultra-high-resolution medical imaging tool with FDA 510(k) clearance that uses OCT to provide clinicians with cross-sectional, real-time margin visualization 1 to 2 mm below the surface of an excised tissue specimen, the company noted in a statement.
The paper, titled “Use of adjunct wide-field optical coherence tomography to visualize margins during breast-conserving surgery for ductal carcinoma in situ: a case series,” was authored by Dr Amelia Tower, a board-certified general surgeon with advanced training in breast surgical oncology based in Fort Worth, Texas.
Perimeter said in the white paper Dr Tower described how she integrated the Perimeter S-Series OCT system into her breast oncology practice.
She concludes that when assisted by Perimeter S-Series OCT in these three case studies, she was able to make intraoperative clinical decisions to excise additional tissue during the primary surgeries, sparing the three patients the need for a second surgery and relieving the associated burden on clinical, economic, and psychosocial resources, Perimeter highlighted.
"We are encouraged and excited by the results from the case studies featured in this newly published white paper,” commented Perimeter CEO Jeremy Sobotta.
“We believe that bringing Perimeter's transformative ultra-high-resolution medical imaging technology directly into the operating room (OR) can assist the surgeon with real-time intraoperative margin visualization – with the aim of improving patient outcomes and reducing healthcare costs.”
The white paper can be found here.
Perimeter is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie